TMEM106B and epilepsy: Validation of the LFQ-MS findings in five cases per group with the semiquantification of immunohistochemistry similarly showed the same trends for TMEM106B, with a 3.9-fold increase in AD vs. epilepsy (p = 0.095) and a 5.0-fold increase in AD vs. control (p = 0.095).